
|Articles|February 6, 2004
Botulinum toxin product study results released
Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
2
New Clinical Insights Into Hair Loss Disorders and the Vitamin D Receptor
3
French Early Access Data on Dupilumab in Pediatric Atopic Dermatitis
4
Phase 2a Evaluation of Dual OX40L/TNFα Antibody Begins in HS
5


















